
Carisoprodol

Homogeneous Enzyme Immunoassay (HEIA™)



Formula: C₁₂H₂₄N₂O₄

Systematic Name: N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate

Brand Names: Soma®

About Carisoprodol: Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. Carisoprodol is known to be metabolized to Meprobamate and Hydroxy-Meprobamate. In 2008, over 10 million prescriptions for Carisoprodol were dispensed. Carisoprodol and Meprobamate are among the 10 most frequently identified drugs in drug-impaired driving cases.¹

Administration: Round white tablets available in 250 mg and 350 mg strengths

Elimination: The major pathway of Carisoprodol metabolism is via the liver by cytochrome enzyme CYP2C19 to form Meprobamate. This enzyme exhibits genetic polymorphism. Patients who are poor CYP2C19 metabolizers have a 4-fold increase in exposure to Carisoprodol, and concomitant 50% reduced exposure to Meprobamate compared to normal CYP2C19 metabolizers. The prevalence of poor metabolizers in Caucasians and African Americans is approximately 3-5% and in Asians is approximately 15-20%.²

Abuse Potential: Carisoprodol is prone to drug dependence, withdrawal and abuse. Carisoprodol is approved only for short-term use (for a maximum of two or three weeks). Taking it for longer periods of time could increase the risk of dependency and possibly abuse.³

Exclusively from Immunalysis

IMMUNALYSIS

Accurate and reliable

Ready to use



- Farrell, L. et al. Recommendations for Toxicological Investigation of Drug Impaired Driving. *Journal of Forensic Sciences*. 52: 1214-1218 (2007).
- 2. Meda Pharmaceuticals Inc. SOMA (Carisoprodol) Product Insert. N-090H2-18 Rev 10/09. Somerset, New Jersey 08873-4120.
- 3. See, S. et al. American Family Physician. 1;78(3): 365-70 (2008).

Soma® is a registered trademark of Meda Pharmaceuticals.







Assay Specifications


Methodology: Homogeneous Enzyme Immunoassay

Cutoff: 100 ng/mL


Calibration Range: 0-500 ng/mL

Overlap: Carisoprodol (100 ng/mL Cutoff)

Precision overlap: Qualitative - 0% overlap between cutoff and \pm 25% controls.



Analytical Recovery: Carisoprodol



ORDER - Carisoprodol (HEIA)

Catalog #	Description
331 -0025 / -0100 / -0500	25 mL / 100 mL / 500 mL Kit
C331-10-1	100 ng/mL Calibrator
C331-10-2	75 and 125 ng/mL Controls
C331-10-5	0, 50, 100, 200 and 500 ng/mL Calibrators
Neg-10-1	10 mL Negative Urine Control

Cross-Reactivity

Analyte	Analyte Concentration (ng/mL)	Carisoprodol Equivalent (ng/mL)	Cross- Reactivity (%)
Carisoprodol	100	100	100
Meprobamate	70	100	143

The following analytes were tested for cross reactivity at 10,000 ng/mL and none were detected: Buprenorphine, Codeine, Dihydrocodeine, Hydrocodone, Hydromorphone, Meperidine, Morphine, Morphine-3-gluc., Naloxone, Naltrexone, Norcodeine, Normorphine, Oxycodone, Oxymorphone, Propoxyphene, Tramadol, Trazodone and Venlafaxine.

	GC-MS Confirm (100 ng/mL)		
		Positive	Negative
HEIA (100 ng/mL)	Positive	44	0
	Negative	0	42

Semi-Quantitative Precision at 100 ng/mL

Interday Precision ($n = 80$)				
Concentration (ng/mL)	Mean Concentration (ng/mL)	CV%		
50 Calibrator	50.3	6.3		
75 Control LOW	77.1	4.9		
100 Calibrator	101.1	4.9		
125 Control HIGH	135.3	5.9		
200 Calibrator	207.4	8.2		
500 Calibrator	505.2	6.7		